Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NTLA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIntellia secures $400M non-dilutive credit facility with OrbiMed, draws $75M upfront
Filed September 4, 2026 · Period ending September 4, 2026 · ~1 min read
Key Changes
-
high
Intellia entered a five-year senior secured credit facility of up to $400 million with OrbiMed as administrative agent and initial lender.
Item 1.01 verify on EDGAR → -
high
$75 million was drawn at closing; remaining capacity is available in tranches tied to FDA approval, revenue targets, equity fundraising, and mutual agreement.
Item 1.01 verify on EDGAR → -
high
Loans bear interest at the greater of 3.00% or one-month SOFR, plus a 6.15% margin — a relatively high-cost financing structure.
Item 1.01 verify on EDGAR → -
high
All obligations are secured on a first-priority basis by substantially all assets, including intellectual property.
Item 1.01 verify on EDGAR → -
medium
The facility matures on September 4, 2031.
Item 1.01 verify on EDGAR →
Summary
Intellia Therapeutics has entered into a $400 million senior secured credit facility with OrbiMed, drawing $75 million upfront. The five-year facility is secured by substantially all of the company's assets, including its intellectual property, and carries an interest rate of the greater of 3.00% or one-month SOFR plus a 6.15% margin. The remaining capacity is available in tranches contingent on regulatory, revenue, and equity financing milestones, with an additional $100 million subject to mutual agreement.
For retail holders, the key takeaway is that Intellia has secured non-dilutive capital to fund its pipeline, particularly the potential approval and launch of lonvoguran ziclumeran for hereditary angioedema. The high interest rate and first-priority collateral reflect the risk profile of a clinical-stage biotech, but the structure avoids immediate equity dilution. The facility's milestone-based tranches mean the full $400 million is not guaranteed and depends on the company's execution.
Section-by-Section Diff
Event · Item 2.03 — Creation of a Direct Financial Obligation
Item 2.03 also reports this as a direct financial obligation (body incorporates the primary Item by reference).
Added in current filing · verify on EDGAR →
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.
The 8-K includes a labeled Item 2.03 section. Its body incorporates the primary Item (typically 1.01) by reference rather than restating terms — do not treat that thinness as 'Item 2.03 absent.' The company is signaling creation of a direct financial obligation alongside the agreement disclosure; keep Item 2.03 visible in the report.
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Credit Facility matures on September 4, 2031 (the “Maturity Date”)
The facility has a five-year term, maturing on September 4, 2031, at which point all outstanding principal is due.
Event · Item 7.01 — Regulation FD Disclosure
Intellia secures a non-dilutive debt facility with OrbiMed for up to $400 million.
Added in current filing · verify on EDGAR →
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million.
Intellia announced a new debt facility with OrbiMed providing up to $400 million in financing. The facility is described as non-dilutive, meaning it does not issue new equity. The press release is furnished as Exhibit 99.1.
Added in current filing · verify on EDGAR →
the availability of the additional $100 million subject to mutual agreement among Intellia and the Lenders
The facility includes an additional $100 million that is available only upon mutual agreement between Intellia and the lenders. This portion is not committed and depends on future negotiations.
Added in current filing · verify on EDGAR →
Intellia’s ability to satisfy the conditions for additional draws under the Credit Facility, including its ability to achieve applicable regulatory, revenue and equity financing milestones
Additional draws under the credit facility are contingent on Intellia achieving certain regulatory, revenue, and equity financing milestones. This means the full $400 million is not immediately available and depends on company performance.
Added in current filing · verify on EDGAR →
the potential approval of lonvoguran ziclumeran for the treatment of hereditary angioedema
The filing references the potential approval of Intellia's drug candidate lonvoguran ziclumeran for hereditary angioedema. This appears to be a key milestone that may be tied to the facility's draw conditions.
Event · Exhibit 99.1
Intellia secures a $400M non-dilutive senior secured term loan facility with OrbiMed, with $75M funded upfront.
Added in current filing · view on EDGAR →
entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed
Intellia announced a new $400 million senior secured term loan facility with OrbiMed, a healthcare investment firm. The facility is described as non-dilutive, meaning it does not issue new equity to shareholders.
Added in current filing · view on EDGAR →
The facility includes an initial term loan of $75 million that was funded at closing
$75 million of the facility was funded immediately at closing. This provides Intellia with near-term capital.
Added in current filing · view on EDGAR →
5 additional tranches totaling up to $225 million that can be drawn at Intellia’s option subject to its achievement of specified milestones related primarily to lonvo-z
Up to $225 million in additional funding is available in five tranches, but only if Intellia achieves specified milestones primarily related to its lonvo-z product candidate. Access to this capital is therefore contingent on development progress.
Added in current filing · view on EDGAR →
an additional $100 million available subject to mutual agreement between the parties during the five-year term of the agreement
A further $100 million may become available, but only if both Intellia and OrbiMed agree to it. This portion is not committed and depends on future negotiation.
Added in current filing · view on EDGAR →
This non-dilutive financing enables us to more freely execute our plan to successfully launch lonvo-z in HAE, advance nexiguran ziclumeran through multiple important milestones in transthyretin amyloidosis and create value through our early pipeline development efforts.
Management states the financing supports the planned U.S. approval and commercial launch of lonvo-z for hereditary angioedema, advancement of nexiguran ziclumeran in transthyretin amyloidosis, and early pipeline development. The facility is intended to provide strategic flexibility through anticipated value inflection points.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 7, 2026 · How we verify